Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021146163 - PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS

Publication Number WO/2021/146163
Publication Date 22.07.2021
International Application No. PCT/US2021/013038
International Filing Date 12.01.2021
IPC
A61K 31/426 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/427 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61K 31/428 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
428condensed with carbocyclic rings
CPC
A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61K 31/428
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
428condensed with carbocyclic rings
Applicants
  • BETA PHARMA, INC. [US]/[US]
Inventors
  • ZHANG, Don
  • PENG, Jirong
  • COSTANZO, Michael John
  • GREEN, Michael Alan
  • GRECO, Michael Nicholas
Agents
  • GARABEDIAN, Todd E.
Priority Data
62/962,39617.01.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS
(FR) DÉRIVÉS PYRIDAZINE ET 1,2,4-TRIAZINE UTILISÉS COMME INHIBITEURS DE FGFR KINASES
Abstract
(EN)
The present invention is directed to inhibitors of fibroblast growth factors, and more particularly to compounds of Formula (I), as well as compositions comprising Formula (I) and methods of using the compound of Formula (I) for the treatment or prevention of a disease, disorder, or medical condition mediated through the fibroblast growth factor receptor (FGFR), especially FGFR1-4. These diseases, disorders, or medical conditions include various cancers.
(FR)
La présente invention concerne des inhibiteurs de facteurs de croissance des fibroblastes, et plus particulièrement des composés de formule (I), ainsi que des compositions comprenant la formule (I) et des méthodes d'utilisation du composé représenté par la formule (I) pour le traitement ou la prévention d'une maladie, d'un trouble ou d'une affection médicale à médiation par le récepteur des facteurs de croissance des fibroblastes (FGFR), en particulier les FGFR1-4. Ces maladies, troubles ou affections médicales comprennent divers cancers.
Latest bibliographic data on file with the International Bureau